Physician profile
Harold Hubert
NPI 1417171307
$6,846.20
in general payments reported to CMS, 2019-2025
31 companies · $954 in 2025
The $954 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $448 · 2021: $667 · 2022: $895 · 2023: $939 · 2024: $2,400 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Travel and Lodging: $854 · Education: $72.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.34 |
| Travel and Lodging | $854.01 |
| Education | $72.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,521.72 | 2021-2025 | |
| Akebia Therapeutics INC | $511.18 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $506.72 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $486.56 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $412.65 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $385.33 | 2019-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $363.37 | 2020-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $340.43 | 2020-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $282.36 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $245.05 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $221.22 | 2021-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $218.43 | 2019-2024 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $195.05 | 2023-2025 | |
| Travere Therapeutics, INC. | $174.69 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $167.81 | 2019-2024 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.99 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $127.78 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $103.24 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $94.50 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $75.75 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $64.53 | 2020-2024 | Gattex |
| Baxter Healthcare | $63.27 | 2022-2024 | Renal - Pd |
| Apellis Pharmaceuticals, INC. | $27.07 | 2025 | Empaveli |
| Novo Nordisk INC | $22.88 | 2024 | Rybelsus, Ozempic |
| Ultragenyx Pharmaceutical INC. | $20.25 | 2020 | |
| Merck Sharp & Dohme LLC | $19.72 | 2025 | Verquvo |
| Ani Pharmaceuticals, INC. | $18.28 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $14.63 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.27 | 2019 | |
| Boston Scientific Corporation | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Hubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.